Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on August 13, 2024. The company is offering up to 6,422,018 shares of common stock and an equal number of pre-funded warrants to purchase common stock. The offering is being conducted on a best-efforts basis by RBW Capital Partners LLC, acting through Dominari Securities LLC, as the sole placement agent. The offering is expected to close one business day after commencement, with the securities delivered upon receipt of investor funds. Virpax intends to use the net proceeds for the development of its product candidate Probudur, working capital, and other general corporate purposes. The company's...Show More

Virpax Pharmaceuticals, Inc. (Virpax), a preclinical-stage pharmaceutical company, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on August 13, 2024. The company is offering up to 6,422,018 shares of common stock and an equal number of pre-funded warrants to purchase common stock. The offering is being conducted on a best-efforts basis by RBW Capital Partners LLC, acting through Dominari Securities LLC, as the sole placement agent. The offering is expected to close one business day after commencement, with the securities delivered upon receipt of investor funds. Virpax intends to use the net proceeds for the development of its product candidate Probudur, working capital, and other general corporate purposes. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'VRPX'. The announcement also details the company's recent developments, including a settlement agreement with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc., compliance with Nasdaq's Minimum Stockholders' Equity Rule, and positive results from a Swine Model pilot study for Probudur.